An observational study in Myopia, sponsored by The University of New South Wales. Recruiting at 5 sites in 2 countries. Open to participants aged 4 Years to 14 Years. Per ClinicalTrials.gov, last updated 2024-12-12.
Sponsored by The University of New South Wales · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 342 studies in Myopia with a site in United States — 27 open to participants now, 44 under way, 3 of them phase 3. Myopia · United States.
Among the 342 studies in Myopia with a site in United States, this one is the 11th largest by planned enrollment of the 46 observational ones that give a count, is one of 31 that started in 2023, is one of 48 observational ones, reaches primary completion later than 9 of the 43 other live ones, and was the 291st registered.
1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.
Browse Myopia studies →27 of the 342 studies in Myopia with a site in United States are open now. Recruiting first, the newest first:
CooperVision International Limited (CVIL) · Sites in United States
Ages 40+
Ohio State University · Sites in United States
Ages 18–38
CooperVision International Limited (CVIL) · Sites in United States, Spain
Ages 7–35
Stanford University · Sites in United States
Ages 22–59
Jaeb Center for Health Research · Sites in United States
Ages 5–11
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.
This study: 4 Years to 14 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
342 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 15 · Phase 4 22
First in 1995; this study’s year is marked. 31 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 230 is above the median of 150 across 205 observational studies indexed under Myopia.
Median enrollment 68 across the 294 interventional studies, 91 across the 46 observational. Of the 279 that completed or were terminated, 175 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
204 of 342 have an industry lead sponsor. The 10 most frequent:
The University of New South Wales is the lead sponsor of 66 studies on the registry; 6 are open to participants now.
The University of New South Wales has 1 study filed under Myopia — fewer than ten, so there is no comparison to draw.
13 of the studies in Myopia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06487897Phase 3VIS, Inc.Phase III Presbyopia Correction Using the VIS Opti-K™ System | 2026-12 |
| NCT06579287Sunhawk Vision Biotech, Inc.A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control | 2026-12 |
| NCT07751172CooperVision International Limited (CVIL)Evaluation of Orthokeratology Lenses With a 5MM Optic Zone Diameter | 2026-12 |
| NCT07679048Rochester Institute of TechnologyMeasuring How Quickly the Eye Focuses After Sustained Viewing of Close-up Images and Videos | 2026-12-15 |
| NCT05893979SightGlass Vision, Inc.Myopia Control Spectacle Lens Cessation Study | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 342 studies in Myopia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Currently, optical and pharmacological interventions have been developed to prevent the progression of childhood myopia. However, no myopia control strategy has been shown to have complete efficacy in controlling myopia progression in children. One possible reason is that risk factors contributing to the development of myopia were not controlled in previous clinical studies including time outdoors and near vision behaviour. This study aims to quantify time spent outdoors and near vision behavior in myopic children and its impact on myopia control efficacy. The outcomes of this study will guide clinicians on risk management and improve responses to existing treatments for progressive myopia.
Myopic children will be recruited from the university based myopia control clinic. Some clinical sites have collaborated with community optometry practices so support recruitment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The Vivior is a wearable clip-on sensor that objectively quantifies near viewing distance and duration, and ambient illumination. The Vivior will be attached to the spectacles frame of children undergoing myopia control treatment.
Near viewing duration
Duration during near tasks
Time frame: 12 months
Near viewing distance
Distance during near tasks
Time frame: 12 months
Outdoor time
Ambient illumination to determine time spent outdoors
Time frame: 12 months
Objective cycloplegic central refraction
Change in objective refraction to measure myopia progression
Time frame: 12 months
Axial length
Change in axial length to measure myopia progression
Time frame: 12 months
Subjective cycloplegic central refraction
Change in subjective refraction to measure myopia progression
Time frame: 12 months
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2023 (actual). Primary completion is estimated for Jun 2026, 39 months after the start.
Of 89 non-industry observational studies under Myopia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 90. This study's planned 39 months is above that.
Counting every sponsor, half of 98 studies reached it within 24 months; a quarter within 10 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The University of New South Wales